支气管扩张症药物市场（2026—2031）
Mordor 预计，支气管扩张症药物市场规模将由2026年的21亿美元增至2031年的32.7亿美元，期间复合年增长率为9.25%。2025年支气管扩张剂占52.56%，吸入制剂占47.76%，医院药房占62.88%。北美为最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
Mordor 预计，支气管扩张症药物市场规模将由2026年的21亿美元增至2031年的32.7亿美元，期间复合年增长率为9.25%。2025年支气管扩张剂占52.56%，吸入制剂占47.76%，医院药房占62.88%。北美为最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 9.25% | 机构预测 |
| 市场规模 | 2026 | USD 2.1 billion | 机构预测 |
| 市场规模 | 2031 | USD 3.27 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| distribution_channel | hospital pharmacies | 2025 | 62.880% |
| geography | North America | 2025 | 42.440% |
| patient_type | adults | 2025 | 58.660% |
| route_of_administration | inhalational products | 2025 | 47.760% |
| treatment | bronchodilators | 2025 | 52.560% |
关键结论
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 62.88%。
- geography 维度中，North America 在 2025 年的公开份额为 42.44%。
- patient_type 维度中，adults 在 2025 年的公开份额为 58.66%。
- route_of_administration 维度中，inhalational products 在 2025 年的公开份额为 47.76%。
- treatment 维度中，bronchodilators 在 2025 年的公开份额为 52.56%。
主要参与者
- AstraZeneca PLC
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising diagnosis of bronchiectasis through high-resolution CT and microbiology | +1.400% | Global, with the strongest impact in North America, Europe, China, Japan, South Korea, and urban Asia-Pacific markets | Medium term (2-4 years) |
| Expansion of disease-modifying therapy following brensocatib approval | +1.200% | North America, Europe, Japan, and selected high-income Asia-Pacific markets | Short term (≤ 2 years) |
| Recurrent exacerbations and long-term antibiotic utilization | +0.900% | Global, with higher relevance in markets with established specialist respiratory care | Medium term (2-4 years) |
| Growing recognition of chronic pseudomonas aeruginosa infection | +0.600% | North America, Europe, Australia, Japan, China, and South Korea | Medium term (2-4 years) |
| Precision stratification by neutrophilic and eosinophilic phenotypes | +0.500% | North America and Europe, followed by Japan and developed Asia-Pacific markets | Medium term (2-4 years) |
| Home-Based Nebulization and Digital Adherence Monitoring | +0.300% | North America, Western Europe, Japan, Australia, and South Korea | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Inhaler-use errors and treatment-adherence gaps | -0.800% | Global, with higher severity in low- and middle-income countries | Medium term (2-4 years) |
| Safety concerns associated with corticosteroids and bronchodilators | -0.700% | Global, with the highest regulatory scrutiny in North America and Europe | Short term (≤ 2 years) |
| Reimbursement friction for long-term inhaled and specialty therapies | -0.500% | Europe, Asia-Pacific, South America, the Middle East and Africa, and other tender-based markets | Medium term (2-4 years) |
| Device burden and adherence challenges in chronic nebulized therapy | -0.400% | Global, with a greater effect in low- and middle-income countries and rural care settings | Medium term (2-4 years) |
报告关注的关键问题
What is driving demand for bronchiectasis drugs?
Earlier diagnosis through specialist respiratory care and the arrival of brensocatib are key factors. The sector is forecast to grow at a 9.25% CAGR from 2026 to 2031.
What is the value of the bronchiectasis drugs sector in 2026?
The value is USD 2.10 billion in 2026 and is forecast to reach USD 3.27 billion by 2031.
Which treatment category has the largest revenue position?
Bronchodilators led treatment revenue with 52.56% in 2025, supported by their established role in respiratory care.
Why are oral therapies gaining importance in bronchiectasis care?
Oral products are forecast to grow at an 11.80% CAGR through 2031. Brensocatib introduced a once-daily oral option designed specifically for NCFB.
Which region is growing fastest for bronchiectasis treatment?
Asia-Pacific is projected to record a 12.25% CAGR through 2031, supported by large patient populations and improving diagnosis.
How concentrated is competition among bronchiectasis drug suppliers?
Insmed is the first mover in disease-specific NCFB treatment, while established respiratory products are supplied by numerous branded and generic manufacturers.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence